KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Deferred Revenue (2016 - 2023)

Jazz Pharmaceuticals (JAZZ) has 14 years of Current Deferred Revenue data on record, last reported at $4000.0 in Q3 2023.

  • For Q3 2023, Current Deferred Revenue fell 99.54% year-over-year to $4000.0; the TTM value through Sep 2023 reached $4000.0, down 99.54%, while the annual FY2022 figure was $463000.0, 77.88% down from the prior year.
  • Current Deferred Revenue reached $4000.0 in Q3 2023 per JAZZ's latest filing, roughly flat from $4000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $10.8 million in Q3 2019 and bottomed at $4000.0 in Q1 2023.
  • Average Current Deferred Revenue over 5 years is $3.2 million, with a median of $2.4 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: grew 8.75% in 2021, then plummeted 99.76% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $9.6 million in 2019, then tumbled by 73.43% to $2.5 million in 2020, then fell by 17.79% to $2.1 million in 2021, then crashed by 77.88% to $463000.0 in 2022, then crashed by 99.14% to $4000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $4000.0 in Q3 2023, $4000.0 in Q2 2023, and $4000.0 in Q1 2023.